Skip to main content
. Author manuscript; available in PMC: 2012 Oct 9.
Published in final edited form as: Ann Rheum Dis. 2012 May 5;71(11):1872–1880. doi: 10.1136/annrheumdis-2011-201180

Figure 3. Dexamethasone attenuates K/BxN arthritis in AnxA1+/+ but not AnxA1−/− mice.

Figure 3

AnxA1+/+ and AnxA1−/− mice were given an intraperitoneal injection of K/BxN serum (50 μl at day 0 and day 2) and then received vehicle or Dex (10 μg i.p. daily). (A) Arthritic scores as monitored over a 10-day time course. *p<0.05 vs. appropriate vehicle control (two-way ANOVA). (B) Right ankles of mice from each experimental group were taken at day 10 and joints processed for staining by H&E and SafraninO. Representative images are shown. Scale bars, 50 μm. (C) Histomorphometric analyses of joint sections; S, synovitis; CE, cartilage erosion; PF, pannus formation. *p<0.05 vs. appropriate vehicle control (Student’s t test). (D) Quantitative real-time PCR was performed on cDNA from left ankle joints; proinflammatory genes were analysed with all Ct values normalised to endogenous Gapdh (4 mice per group). RQ values were calculated using 2−(ΔΔCt) and data shown here as mean % gene inhibition by Dex relative to vehicle control groups ± SE. Naïve joints were set as the calibrator samples. *p<0.05 vs. respective vehicle control (Student’s t test).